agDisclosure Now Supports Version 10 of the European Clinical Trials Database (EudraCT)
ArisGlobal, a leading provider of solutions to the life sciences industry, has announced that agDisclosure, its clinical trial disclosure solution, now supports Version 10 of the European Medicines Agencys EudraCT database
STAMFORD, CT- January 28, 2015- ArisGlobal, a leading provider of solutions to the life sciences industry, has announced that agDisclosure, its clinical trial disclosure solution, now supports Version 10 of the European Medicines Agency’s EudraCT database (European Union Drug Regulating Authorities Clinical Trials). EudraCT Version 10 makes the reporting of summary results mandatory to EudraCT, including those for legacy studies by July 2015 or July 2016, depending on the age of the trial. agDisclosure now supports reporting of results to both ClinicalTrials.gov and EudraCT, allowing customers to use ClinicalTrials.gov data and transform it to EudraCT data.
“Companies need to comply with the requirements from CT.GOV and EudraCT, both of which make results reporting mandatory,” stated Simon Sparkes, Executive Vice President, Product Strategy, ArisGlobal. “Consistency of the data published between different registries is another concern for many companies. agDisclosure provides a central area where protocol and results data sets are created for both CT.GOV and EudraCT. This approach, combined with automated workflow and approval routing ensures consistency of the data and allows users to register protocols and submit result data as efficiently as possible.”
agDisclosure supports the complete trial disclosure process – from gathering required data, reviews by stakeholders, conducting checks against registry-specific validation rules, to generating XML files for upload and automatic submission. It is available to customers as a hosted solution via agOnDemand™, ArisGlobal's highly proven Software-as-a-Service (SaaS) delivery platform. A free version of agDisclosure is also available for ClinicalTrials.gov; interested companies can learn more by visiting http://totalclinical.com/agdisclosure-free-basic-edition.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
